Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2022), 10.1038/s41433-022-02092-5)

David R. Lally*, Anat Loewenstein, Jennifer J. Arnold, Yit C. Yang, Kinfemichael Gedif, Catherine Best, Hersh Patel, Ramin Tadayoni, Jeffrey S. Heier

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

The article “Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies”, written by David R. Lally, Anat Loewenstein, Jennifer J. Arnold, Yit C. Yang, Kinfemichael Gedif, Catherine Best, Hersh Patel, Ramin Tadayoni, Jeffrey S. Heier, was originally published electronically on the publisher’s internet portal on 21 May 2022 without open access.

Original languageEnglish
JournalEye
DOIs
StateAccepted/In press - 2022

Fingerprint

Dive into the research topics of 'Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies (Eye, (2022), 10.1038/s41433-022-02092-5)'. Together they form a unique fingerprint.

Cite this